Novel Approaches to Target HER2-positive Breast Cancer: Trastuzumab Emtansine

Cancer Management and Research- New Zealand

doi 10.2147/cmar.s104447

Full Text

Abstract

Available in

Date

May 1, 2016

Authors

Bernardo Amadeo Leone

Publisher

Informa UK Limited

Related search

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer

International Journal of Breast Cancer

English

Personalized Drug Combinations to Overcome Trastuzumab Resistance in HER2-positive Breast Cancer

Biochimica et Biophysica Acta - Reviews on Cancer

English

P3-013a Phase 1b Study of S-1 Combined With Trastuzumab Emtansine (T-Dm1) for HER2 Positive Metastatic Breast Cancer

English

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine

Medicine

2005

English

Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells

Molecular Cancer Therapeutics

Cancer Research

Oncology

2018

English

Src, a Potential Target for Overcoming Trastuzumab Resistance in HER2-positive Breast Carcinoma

British Journal of Cancer

Cancer Research

Oncology

2014

English

Relationship Between Tumor Biomarkers and Efficacy in MARIANNE, a Phase III Study of Trastuzumab Emtansine ± Pertuzumab Versus Trastuzumab Plus Taxane in HER2-positive Advanced Breast Cancer

English

Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib

AboutOpen

2018

English

A Randomized, Controlled Phase II Trial of Neoadjuvant Ado-Trastuzumab Emtansine, Lapatinib, and Nab-Paclitaxel Versus Trastuzumab, Pertuzumab, and Paclitaxel in HER2-positive Breast Cancer (TEAL Study)

Breast Cancer Research

Cancer Research

Oncology

2019

English

Amanote Research

Novel Approaches to Target HER2-positive Breast Cancer: Trastuzumab Emtansine

Cancer Management and Research- New Zealand

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer

Personalized Drug Combinations to Overcome Trastuzumab Resistance in HER2-positive Breast Cancer

P3-013a Phase 1b Study of S-1 Combined With Trastuzumab Emtansine (T-Dm1) for HER2 Positive Metastatic Breast Cancer

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells

Src, a Potential Target for Overcoming Trastuzumab Resistance in HER2-positive Breast Carcinoma

Relationship Between Tumor Biomarkers and Efficacy in MARIANNE, a Phase III Study of Trastuzumab Emtansine ± Pertuzumab Versus Trastuzumab Plus Taxane in HER2-positive Advanced Breast Cancer

Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib

A Randomized, Controlled Phase II Trial of Neoadjuvant Ado-Trastuzumab Emtansine, Lapatinib, and Nab-Paclitaxel Versus Trastuzumab, Pertuzumab, and Paclitaxel in HER2-positive Breast Cancer (TEAL Study)